Currently, there are 3.38B common shares owned by the public and among those 3.38B shares have been available to trade.
The company’s stock has a 5-day price change of 8.48% and 17.17% over the past three months. NVO shares are trading 14.32% year to date (YTD), with the 12-month market performance up to 78.72% higher. It has a 12-month low price of $67.63 and touched a high of $116.12 over the same period. NVO has an average intraday trading volume of 4.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.43%, 13.84%, and 28.39% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Novo Nordisk ADR (NYSE: NVO) shares accounts for 8.87% of the company’s 3.38B shares outstanding.
It has a market capitalization of $400.12B and a beta (3y monthly) value of 0.41. The stock’s trailing 12-month PE ratio is 43.78, while the earnings-per-share (ttm) stands at $2.70. The company has a PEG of 15.63 and a Quick Ratio of 0.64 with the debt-to-equity ratio at 0.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.95% over the week and 1.53% over the month.
Analysts forecast that Novo Nordisk ADR (NVO) will achieve an EPS of $0.78 for the current quarter, $0.79 for the next quarter and $3.88 for 2025. The lowest estimate earnings-per-share for the quarter is $0.78 while analysts give the company a high EPS estimate of $0.79. Comparatively, EPS for the current quarter was $0.64 a year ago. Earnings per share for the fiscal year are expected to increase by 21.46%, and 20.29% over the next financial year. EPS should shrink at an annualized rate of 2.80% over the next five years, compared to 16.48% over the past 5-year period.
Looking at the support for the NVO, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on January 23, 2024, with the firm’s price target at $120.
